EpimAb Biotherapeutics is a clinical-stage biopharmaceutical company developing proprietary bispecific antibody therapeutics using its FIT-Ig® (Fabs-In-Tandem Immunoglobulin) platform. The company focuses on oncology and other high‑value therapeutic areas and is building a pipeline of both clinical and preclinical bispecific programs. Its lead candidates—EMB-01 (EGFR/cMET), EMB-02 (PD-1/LAG-3) and EMB-06 (CD3/BCMA)—are advancing through clinical development in China, the U.S. and Australia. Proceeds from the Series C will fund ongoing clinical development of these three assets and expand the company’s pipeline of novel bispecifics and other biologics. EpimAb maintains research and manufacturing facilities in Shanghai and Suzhou and intends to selectively license platform and pipeline assets to partners worldwide. The company emphasizes translating its FIT-Ig platform into differentiated clinic-ready molecules with global potential. EpimAb Biotherapeutics is a Shanghai-based R&D biotech focused on generating bispecific antibody therapeutics via its proprietary FIT-Ig® (Fabs-In-Tandem Immunoglobulin) platform. The company is advancing a clinical PhI/II program, EMB01, and is building a pipeline concentrated on immuno-oncology and other high-unmet-need areas. Management includes founder and CEO Chengbin Wu, COO/CBO Stephan Lensky, and CMO Bin Peng, who lead discovery, financing/BD, and translational/clinical development respectively. With the Series B close, EpimAb plans to expand development and manufacturing capacity, adding a new CMC site in Suzhou for process development and pilot manufacturing. The company also pursues selective licensing of its platform to diversify its pipeline and partner globally. Financially, the Series B brings recent financing to $74M and total funding to over $100M to support near-term clinical and manufacturing initiatives. EpimAb Biotherapeutics is a privately owned biopharmaceutical R&D company based in Shanghai, founded in 2015, focused on generating bispecific molecules with antibody-like properties using its FIT-Ig® (Fabs-In-Tandem Immunoglobulin) platform. The FIT-Ig technology is designed to be more potent, less immunogenic and easier to manufacture. EpimAb is building a pipeline of novel bispecific antibody therapeutics centered on immuno-oncology and other areas with high unmet medical need, and seeks to diversify via selective licensing and strategic partnerships. The company says its platform was validated through early partnerships with biopharmaceutical companies in China and abroad. Management plans to advance its lead oncology program toward the clinic, anticipating submission of an IND and the start of a first clinical trial in 2018. Leadership includes founder and CEO Dr. Chengbin Wu, inventor of FIT-Ig®, and Dr. Stephan Lensky as COO and CBO.

Total raised

$219M

Funding rounds

3

Latest round

Series C

Latest activity

Mar 2021